About Immago Biosystems

About company

Immago Biosystems Ltd was founded in 2013 from research arising in the Oxford Glycobiology Institute within the Department of Biochemistry at the University of Oxford. Dr Chris Scanlan and Dr Max Crispin invented ‘receptor refocusing’ which aims to enhances immune-mediated killing of cancer cells by modulating the endogenous antibody repertoire with enzymes such as IdeS and EndoS. Together with their colleague, Dr Kavitha Baruah, they formed Immago Biosystems Ltd to help bring these concepts to the clinic.